Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (OTCQB: BTCY) is a Nevada‑incorporated medical technology and Technology‑as‑a‑Service (TaaS) company that focuses on remote monitoring, diagnostic solutions, and chronic disease management, with a strong emphasis on cardiac care. This news page aggregates company announcements, financial updates, and operational developments related to BTCY.
Readers can follow earnings and financial results updates, where Biotricity discusses themes such as recurring technology fees, margins, operating efficiency, and the role of proprietary AI‑driven automation in its TaaS model. The company frequently issues press releases around quarterly and annual results, often accompanied by details of investor conference calls and webcasts.
News items also cover product and platform developments, including Biotricity’s Biocore suite of cardiac monitoring products, the Biocore Pro next‑generation cardiac monitoring device, and the Cardiac AI Cloud platform. Announcements have highlighted the use of large volumes of anonymized heartbeat data to support diagnostic accuracy and remote cardiac care.
Another important category of BTCY news involves strategic collaborations and partnerships. Examples include Biotricity’s collaboration with Health‑E Commerce to make its Bioheart 24/7 wearable cardiac monitoring solution available to FSA and HSA users, and its work with B‑Secur to expand a device‑neutral cardiac monitoring platform that integrates ECG data from consumer wearables into a cloud‑based medical workflow.
Investors and healthcare professionals can use this page to track Biotricity’s communications on remote patient monitoring, cardiac diagnostics, intellectual property milestones, and access to hospital networks and managed care channels. For those following BTCY, returning to this page provides a centralized view of the company’s latest public disclosures and press releases.
Biotricity (BTCY) reported Q3 FY22 financial results with a remarkable 93% year-over-year revenue increase to $1.93 million, outpacing the 40% increase in SG&A. The company's cash position reached a historic $16.8 million. Despite a net loss of $7.34 million due to one-time expenses, adjusted loss is $6.0 million. Biotricity anticipates continued triple-digit revenue growth for the full year, fueled by the launch of innovative products like Bioheart and the FDA-cleared Biotres, expanding its addressable market significantly.
SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.
Biotricity (NASDAQ:BTCY) is set to release its third quarter fiscal 2022 financial results on February 14, 2022, after the market closes. Management will discuss the results during a conference call on February 15, 2022, at 4:15 p.m. EST. The company anticipates 2022 as a breakout year, emphasizing the commercial launch of Bioheart and FDA clearance for Biotres. Biotricity focuses on remote health monitoring and chronic care management, aiming to enhance preventive and personal care for patients.
Biotricity, Inc. (NASDAQ:BTCY) has received 510(k) clearance from the FDA for its Biotres cardiac monitoring device, targeting the $2 billion holter market.
This innovative device allows continuous 3-channel ECG recordings for lower-risk patients, with features including a rechargeable battery, wireless connectivity, and user-friendly design. Biotres expands Biotricity's Total Addressable Market from $1 billion to $5.7 billion, with sales expected to begin on April 1, 2022. The CEO emphasizes its potential to enhance cardiac care and reduce costs.
Biotricity Inc. (NASDAQ:BTCY) has launched its Bioheart heart monitor system on Amazon.com, enhancing consumer access to advanced cardiac monitoring without a prescription. Priced at $199, the device is available for a limited introductory price of $149. The Bioheart offers continuous 24/7 data collection, advanced analytics, and innovative features like retrospective snapshots of heart data. This expansion not only opens new revenue streams for Biotricity but also targets a $1.24B market. The product aims to transform cardiac health monitoring through a virtual cardiac clinic ecosystem.
Biotricity Inc. (NASDAQ:BTCY) has successfully completed a $12 million non-convertible debt financing with SWK Funding LLC to replace existing debt and support inventory and annual recurring revenue (ARR) subscriptions. The financing includes a five-year term with an interest-only period of two years, leading to a 40% balloon payment at maturity. This capital infusion strengthens Biotricity's balance sheet without diluting equity shareholders and positions the company for upcoming product launches in 2022.
Biotricity (NASDAQ:BTCY) has released its December 2021 CEO Shareholder Letter, outlining key milestones and growth strategies for 2022. The Company reports a record quarterly revenue of $1.81 million, representing a 143% year-over-year increase. Significant achievements include its recent uplisting to Nasdaq, aimed at attracting institutional investors and enhancing liquidity. The shareholder letter highlights the successful commercialization of the Biokit and outlines future goals, including the launch of innovative cardiac monitoring solutions.
Biotricity (NASDAQ:BTCY) has launched Bioheart, an innovative heart monitor that allows users to access continuous heart monitoring technology directly via a smartphone app. Bioheart targets a growing market valued at
Biotricity Inc. (NASDAQ:BTCY) reported its tenth consecutive quarter with triple-digit year-over-year revenue growth, achieving $1.81 million in Q2-FY22, a 143% increase compared to the prior year. The company incurred a net loss of $11 million, primarily due to $5.46 million in one-time expenses linked to its Nasdaq up-listing. Biotricity's balance sheet is robust, with $11.7 million in cash. The company introduced Biokit, a home-use cardiac monitoring device anticipated to launch in early 2022, indicating a strong product pipeline aimed at improving patient outcomes.
Biotricity, Inc. (BTCY) has announced the release of its financial results for the second quarter, ending September 30, 2021, scheduled for November 4, 2021, after market close. The company will host a conference call and live webcast at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Biotricity focuses on remote health monitoring solutions, aiming to enhance preventive and personal care for chronic conditions.
FAQ
What is the current stock price of Biotricity (BTCY)?
What is the market cap of Biotricity (BTCY)?
